Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

ease) in accrued expenses to contract manufacturers - (40,444) Increase (decrease) in deferred revenue (4,111) (5,321) Increase (decrease) in other liabilities (995) (1,215) ---- ------ Net cash used in operating activities $(71,077) $(96,425) Cash flows from investing activities: Purchases of investments (186,016) (334,685) Sales of investments 7,627 28,590 Maturities of investments 221,948 369,337 Transaction costs from Novartis pulmonary asset sale (4,440) Purchases of property and equipment (7,999) (10,349) ------ ------- Net cash provided by investing activities $31,120 $52,893 Cash flows from financing activities: Payments of loan and capital lease obligations (616) (1,151) Proceeds from issuances of common stock 90 383 --- --- Net cash used in financing activities $(526) $(768) ----- ----- Effect of exchange rates on cash and cash equivalents (109) (164) ---- ---- Net decrease in cash and cash equivalents $(40,592) $(44,464) Cash and cash equivalents at beginning of period 155,584 76,293 ------- ------ Cash and cash equivalents at end of period $114,992 $31,829
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... DIEGO , Oct. 20, 2014   BioNano Genomics ... Irys system: the ability to collect human data at 30X ... a single chip.  This new capability was established and demonstrated ... the Irys TM System and will be ... two months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... are only 24 hours in a day, that doesn’t seem to ... within their busy schedules for exercise and fitness. Fortunately, one does ... in shape. Here are five ways you can reach your fitness ... Your Commute , Consider riding a bike or taking the bus ... routine. If you must use your car to get to work, ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... health, , THURSDAY, Feb. 18 (HealthDay News) -- New research ... a lot and those who have them less often: The ... more depressed. , The finding comes from a study ... episodic, if they occurred no more than 14 days a ...
... ... than later, says substance abuse expert Glenn Williams in his new Authentic/Biblica book, Talking Smack ... (PRWEB) February 18, 2010 ... COO Glenn Williams, a psychologist and substance abuse expert who has worked with parents and ...
... ... Carnie Wilson, will host a blog on The Fresh Diet, chronicling her quest to whittle ... Corner at blog.thefreshdiet.com where the daughter of the legendary Beach Boy, Brian Wilson, will discuss ... , ...
... ... related Q&A and social networking site, grows and adds new offerings, including answer customization ... ... SciAnswers.com , launched just over three months ago in November 2009 as a science ...
... ... freight import records from the public. Meanwhile, Microsoft, Google and Sony continue to import ... ... 17, 2010 -- Trade Privacy LLC , a trade data protection company, just ...
... , , , ... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of ... and assisted living companies, today reported record results for the fourth ... , Financial Highlights Include: , Total ...
Cached Medicine News:Health News:Talking Smack to Keep Kids Drug-Free 2Health News:Talking Smack to Keep Kids Drug-Free 3Health News:Carnie Wilson Blogs On The Fresh Diet 2Health News:SciAnswers.com Grows and Adds a Technical and Healthcare Professionals Job Board. 2Health News:SciAnswers.com Grows and Adds a Technical and Healthcare Professionals Job Board. 3Health News:Trade Privacy LLC: Research Concludes Apple Inc. Has Blocked Their Import Records from Public Access 2Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 2Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 3Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 4Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 5Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 6Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 7Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 8Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 9Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 10Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 11Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 12Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 13Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 14Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 15Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 16
... 2000 assays are designed ... IMMULITE 2000, a high-throughput, ... analyzer. IMMULITE 2000 offers ... and a rapidly expanding ...
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...
Medicine Products: